Amgen's Rocatinlimab Asthma Treatment Shows Promise in Phase 2 Study

Amgen announced an update on its Phase 2 study of Rocatinlimab, a potential asthma treatment. The study aims to evaluate the drug's effectiveness in reducing asthma exacerbations. Rocatinlimab is administered via subcutaneous injection and is compared to a placebo. The study began in May 2024 and is ongoing, with recruitment currently underway. If successful, Rocatinlimab could positively impact Amgen's stock performance and position the company as a leader in asthma treatment.

Amgen Inc. (AMGN) has announced an update on its ongoing Phase 2 clinical study of rocatinlimab, a potential treatment for moderate-to-severe asthma. The study, titled "A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma," aims to evaluate the drug's effectiveness in reducing asthma exacerbations.

The study began on May 24, 2024, and is currently ongoing with recruitment still underway. Rocatinlimab is administered via subcutaneous injection and is being compared to a placebo. The primary goal of the study is to assess the drug's efficacy and safety in comparison to the placebo. If successful, rocatinlimab could provide a new therapeutic option for asthma patients and potentially reduce the frequency and severity of asthma attacks.

The study employs a randomized, parallel assignment model with double masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide a new therapeutic option for asthma patients. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.

For investors, this study could positively influence Amgen’s stock performance if rocatinlimab proves effective. A successful outcome could position the company as a leader in asthma treatment and impact competitors in the respiratory treatment market. The study is currently recruiting, with further details available on the ClinicalTrials portal.

In addition to the study update, Amgen also reported strong financial performance in its latest quarter. The company reported an earnings per share (EPS) of $6.02, exceeding analysts' expectations of $5.28. Revenue was $9.18 billion, up 9.4% year-over-year. The company also announced a quarterly dividend of $2.38 per share, yielding 3.2%.

Several institutional investors have increased their stakes in Amgen, including CW Advisors LLC, which raised its stake by 5.5% in the first quarter. Other notable investors include Brighton Jones LLC, Forum Financial Management LP, Transce3nd LLC, Dark Forest Capital Management LP, and Pinebridge Investments L.P.

Amgen's stock performance has been relatively stable, with shares trading around $296.45 as of Thursday. The stock has a market capitalization of $159.60 billion, a PE ratio of 24.24, and a beta of 0.49. Analysts have set varying price targets and ratings for the stock, with an average rating of "Hold" and an average price target of $303.76.

References:
[1] https://www.tipranks.com/news/company-announcements/amgens-promising-asthma-treatment-rocatinlimab-study-update
[2] https://www.marketbeat.com/instant-alerts/filing-amgen-inc-amgn-shares-bought-by-cw-advisors-llc-2025-08-21/